Novo Nordisk Income from Continuous Operations 2010-2024 | NVO

Novo Nordisk annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
  • Novo Nordisk income from continuous operations for the quarter ending September 30, 2024 was $4.024B, a 22.62% increase year-over-year.
  • Novo Nordisk income from continuous operations for the twelve months ending September 30, 2024 was $13.792B, a 27.22% increase year-over-year.
  • Novo Nordisk annual income from continuous operations for 2023 was $12.151B, a 54.54% increase from 2022.
  • Novo Nordisk annual income from continuous operations for 2022 was $7.862B, a 3.48% increase from 2021.
  • Novo Nordisk annual income from continuous operations for 2021 was $7.598B, a 17.7% increase from 2020.
Novo Nordisk Annual Income from Continuous Operations
(Millions of US $)
2023 $12,151
2022 $7,862
2021 $7,598
2020 $6,456
2019 $5,839
2018 $5,906
2017 $5,792
2016 $5,636
2015 $5,187
2014 $4,722
2013 $4,485
2012 $3,703
2011 $3,030
2010 $2,660
2009 $2,014
Novo Nordisk Quarterly Income from Continuous Operations
(Millions of US $)
2024-09-30 $4,024
2024-06-30 $2,893
2024-03-31 $3,699
2023-12-31 $3,175
2023-09-30 $3,282
2023-06-30 $2,838
2023-03-31 $2,855
2022-12-31 $1,866
2022-09-30 $1,949
2022-06-30 $1,904
2022-03-31 $2,143
2021-12-31 $1,665
2021-09-30 $1,922
2021-06-30 $1,965
2021-03-31 $2,046
2020-12-31 $1,512
2020-09-30 $1,617
2020-06-30 $1,569
2020-03-31 $1,757
2019-12-31 $1,285
2019-09-30 $1,519
2019-06-30 $1,445
2019-03-31 $1,590
2018-12-31 $1,066
2018-09-30 $1,410
2018-06-30 $1,656
2018-03-31 $1,775
2017-12-31 $1,320
2017-09-30 $1,544
2017-06-30 $1,472
2017-03-31 $1,456
2016-12-31 $1,253
2016-09-30 $1,470
2016-06-30 $1,514
2016-03-31 $1,398
2015-12-31 $1,204
2015-09-30 $1,250
2015-06-30 $1,236
2015-03-31 $1,497
2014-12-31 $1,093
2014-09-30 $1,157
2014-06-30 $1,285
2014-03-31 $1,186
2013-12-31 $1,107
2013-09-30 $1,139
2013-06-30 $1,180
2013-03-31 $1,059
2012-12-31 $1,005
2012-09-30 $953
2012-06-30 $924
2012-03-31 $822
2011-12-31 $831
2011-09-30 $786
2011-06-30 $798
2011-03-31 $747
2010-12-31 $729
2010-09-30 $668
2010-06-30 $627
2010-03-31 $596
2009-12-31 $460
2009-09-30 $547
2009-06-30 $547
2009-03-31 $480
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $460.555B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94